Jason Lettmann Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Jason Lettmann.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Jason Lettmann. Jason Lettmann is Director in Ra Pharmaceuticals, Inc. ($RARX) and Director in ALX ONCOLOGY HOLDINGS INC ($ALXO).
Latest Insider Trading Transactions of Jason Lettmann
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 15 2021 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Option Exercise | A | 59.66 | 12,004 | 716,159 | 12,004 | |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 38,660 | 0 | 0 | |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 664,660 | 0 | 0 | |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 18,705 | 0 | 0 | |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 137,286 | 0 | 0 | |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 10,529 | 0 | 0 | |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 11,110 | 0 | 0 | |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 150,801 | 0 | 0 | |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 8,175 | 0 | 0 | |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 59,998 | 0 | 0 | |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 39,758 | 0 | 0 | |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 683,523 | 0 | 0 | |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 222,752 | 0 | 0 | |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 1,633,743 | 0 | 0 | |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 78,175 | 0 | 0 | |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Buy | C | 0.00 | 111,528 | 0 | 120,212 | 8.7 K to 120.2 K (+1,284.29 %) |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Buy | P | 19.00 | 22,000 | 418,000 | 22,000 | 0 to 22 K |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Buy | C | 0.00 | 1,498,984 | 0 | 2,023,469 | 524.5 K to 2 M (+285.80 %) |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Buy | P | 19.00 | 378,000 | 7,182,000 | 378,000 | 0 to 378 K |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Buy | C | 0.00 | 249,632 | 0 | 309,222 | 59.6 K to 309.2 K (+418.92 %) |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Buy | C | 0.00 | 1,831,027 | 0 | 2,268,087 | 437.1 K to 2.3 M (+418.94 %) |
| Jul 21 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Buy | C | 0.00 | 88,704 | 0 | 107,220 | 18.5 K to 107.2 K (+479.07 %) |
| Jul 17 2020 | ALXO | ALX ONCOLOGY HOLDI ... | Lettmann Jason | Director | Option Exercise | A | 19.00 | 24,009 | 456,171 | 24,009 | |
| Jun 22 2017 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Option Exercise | A | 22.37 | 15,000 | 335,550 | 15,000 | |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 481,503 | 0 | 0 | |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 3,533,875 | 0 | 0 | |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 517,617 | 0 | 0 | |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 3,798,914 | 0 | 0 | |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 3,408,439 | 0 | 0 | |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 3,664,071 | 0 | 0 | |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Option Exercise | C | 0.00 | 9,744,916 | 0 | 0 | |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Option Exercise | X | 0.07 | 63,019 | 4,411 | 0 | |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | P | 13.00 | 15,633 | 203,229 | 4,066,503 | 4.1 M to 4.1 M (+0.39 %) |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | P | 13.00 | 114,752 | 1,491,776 | 4,050,870 | 3.9 M to 4.1 M (+2.92 %) |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | P | 13.00 | 263,538 | 3,425,994 | 3,936,118 | 3.7 M to 3.9 M (+7.18 %) |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | C | 0.00 | 68,786 | 0 | 3,672,580 | 3.6 M to 3.7 M (+1.91 %) |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | C | 0.00 | 504,839 | 0 | 3,603,794 | 3.1 M to 3.6 M (+16.29 %) |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | C | 0.00 | 73,945 | 0 | 3,098,955 | 3 M to 3.1 M (+2.44 %) |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | C | 0.00 | 542,702 | 0 | 3,025,010 | 2.5 M to 3 M (+21.86 %) |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | C | 0.00 | 486,919 | 0 | 2,482,308 | 2 M to 2.5 M (+24.40 %) |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | C | 0.00 | 523,438 | 0 | 1,995,389 | 1.5 M to 2 M (+35.56 %) |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | C | 0.00 | 1,392,130 | 0 | 1,471,951 | 79.8 K to 1.5 M (+1,744.06 %) |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Sell | S | 13.00 | 340 | 4,420 | 79,821 | 80.2 K to 79.8 K (-0.42 %) |
| Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Lettmann Jason | Director | Buy | X | 0.07 | 63,019 | 4,411 | 80,161 | 17.1 K to 80.2 K (+367.63 %) |
Page: 1